Post date: 2009/8/17 下午 02:42:44
轉載自 AuntMinnie.com staff writers, August 14, 2009
The U.S. Centers for Medicare and Medicaid Services (CMS) is recommending national reimbursement coverage for FDG-PET for the initial staging of cervical cancer, concluding that the modality can make "meaningful changes in therapeutic management and improve health outcomes."
CMS proposes to cover the use of one FDG-PET exam for staging in beneficiaries who have biopsy-proven cervical cancer when the beneficiary's treating physician determines that the FDG-PET study is needed to determine the location and/or extent of the tumor for the following therapeutic purposes related to the initial treatment strategy:
- To determine whether the beneficiary is an appropriate candidate for an invasive diagnostic or therapeutic procedure
- To determine the optimal anatomic location for an invasive procedure
- To determine the anatomic extent of tumor when the recommended antitumor treatment reasonably depends on the extent of the tumor